Motor Neurone Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any race or ethnicity, male or female
- People who do not currently have any symptoms of ALS or a related condition called fronto-temporal dementia
- People who have already had genetic testing that found a gene linked to ALS
- People who have a parent, sibling, or child who is a confirmed carrier of a gene linked to ALS
- People who have a parent, sibling, or child who has or had ALS with a confirmed related gene mutation, or who come from a family with multiple ALS diagnoses and a known related gene mutation
- People considered by the study team to be at high risk of carrying an ALS-related gene mutation, based on a review of family history and genetic information
- People who are willing to have genetic analysis done, with the choice of whether or not to be told the results
- People who are able to travel to Columbia University Irving Medical Center every 6 to 24 months for study visits
- People who are able to understand and agree to the study procedures, or who have a legally authorised representative who is able to do this on their behalf
Who may not be able to join:
- People with a known diagnosis of HIV (this applies to the part of the study involving biological sample collection)
- People with a known diagnosis of hepatitis B (this applies to the part of the study involving biological sample collection)
- People with a known diagnosis of hepatitis C (this applies to the part of the study involving biological sample collection)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Matthew Harms, MD, Columbia University
Phone: 347-852-5315
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to emergence of symptoms attributable to gene mutations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.